FDA approval of semaglutide could help Novo Nordisk access unexploited obesity market

Before the end of the week, the FDA will reveal its verdict on Novo Nordisk's obesity treatment semaglutide. According to Sydbank analyst Søren Løntoft Hansen, this is a crucial approval for the Danish pharmaceutical company.
Photo: Stine Tidsvilde
Photo: Stine Tidsvilde

On Friday at the latest, the US Food and Drug Administration (FDA) will decide whether to approve Novo Nordisk's molecule semaglutide for treating obesity.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading